CRISPR-Cas12a2 selectively eliminates yeast and human cells via RNA-triggered DNA shredding
Updated
Updated · Nature.com · May 5
CRISPR-Cas12a2 selectively eliminates yeast and human cells via RNA-triggered DNA shredding
11 articles · Updated · Nature.com · May 5
In Nature, Scholz, Thompson, Crosby and colleagues report 134-fold yeast reduction, 86% depletion of HeLa-GFP cells, and no measurable off-target activation in tested human cells.
Activated by target transcripts, Cas12a2 caused widespread double-strand DNA breaks and mainly apoptotic death, while selectively removing HPV-harbouring cells, enriching gene-edited cells and targeting KRAS G12C-mutant cancer cells.
The work addresses a longstanding gap in eukaryotic CRISPR counterselection and suggests applications in medicine, biotechnology and agriculture, though further optimisation of targeting, delivery and safety will be needed.
Can this 'genomic paper shredder' truly deliver cancer therapy with zero collateral damage to healthy tissues?
As this new 'kill switch' targets cancer, how will tumor cells evolve to outsmart the technology?
This cellular self-destruct works in a lab, but how can it be safely delivered inside the human body?
Cas12a2 CRISPR Breakthrough: 50% Tumor Reduction and 90% Viral Cell Elimination via Programmable Cell Self-Destruction
Overview
In May 2026, an international collaboration announced a breakthrough CRISPR discovery involving Cas12a2, a protein that, when activated by specific RNA, indiscriminately destroys single-stranded DNA, triggering targeted cell death. This mechanism enables precise elimination of diseased cells, demonstrated by a 50% tumor reduction in cancer models and over 90% clearance of HPV-infected cells, while sparing healthy cells. Unlike traditional gene-editing tools, Cas12a2 acts as a programmable self-destruct switch, opening new therapeutic possibilities for cancer, viral infections, and age-related diseases. Although promising, challenges in safe delivery, manufacturing, and cost remain before clinical use, prompting cautious optimism among experts.